

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

UWB1.289+BRCA1

RRID:CVCL_B078

Type: Cell Line

Proper Citation

RRID:CVCL_B078

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B078

Proper Citation: RRID:CVCL_B078

Description: Cell line UWB1.289+BRCA1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: BRCA1 syndrome

Defining Citation: [PMID:17259345](#), [PMID:25230021](#)

Comments: Characteristics: Due to the high expression of the transfected wild-type BRCA1 gene, this cell line is partially rescued in term of its response to DNA damage., Population: Caucasian., Part of: OCCP ovarian cancer cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: UWB1.289+BRCA1

Cross References: BTO:BTO_0006254, ATCC:CRL-2946, GEO:GSM1291154, Wikidata:Q54992391

ID: CVCL_B078

Hierarchy: cvcl_b079

Record Creation Time: 20220427T221706+0000

Record Last Update: 20260830T000247+0000

Ratings and Alerts

No rating or validation information has been found for UWB1.289+BRCA1.

No alerts have been found for UWB1.289+BRCA1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Suresh S, et al. (2025) PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. *Scientific reports*, 15(1), 36766.

Bedia JS, et al. (2025) Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models. *Cell reports. Medicine*, 6(9), 102295.

Sogari A, et al. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. *Cell reports. Medicine*, 5(2), 101376.

Rutkowska A, et al. (2024) Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation. *Cancer research communications*, 4(9), 2427.

Allard D, et al. (2023) The CD73 immune checkpoint promotes tumor cell metabolic fitness. *eLife*, 12.

Hromas R, et al. (2022) BRCA1 mediates protein homeostasis through the ubiquitination of PERK and IRE1. *iScience*, 25(12), 105626.

Tirman S, et al. (2021) Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. *Molecular cell*, 81(19), 4026.

Swift ML, et al. (2021) DSB repair pathway choice is regulated by recruitment of 53BP1 through cell cycle-dependent regulation of Sp1. *Cell reports*, 34(11), 108840.

Taglialatela A, et al. (2021) REV1-Pol η maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps. *Molecular cell*, 81(19), 4008.

Bruand M, et al. (2021) Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. *Cell reports*, 36(3), 109412.

Bellio C, et al. (2019) The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells. *Cancers*, 11(11).

Ding L, et al. (2018) PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. *Cell reports*, 25(11), 2972.